Ajinomoto to buy gene therapy CDMO Forge Biologics in $620M all-cash deal
CDMO and biotech Forge Biologics will be acquired by Ajinomoto in an all-cash deal worth $620 million, a move that will see the Japan-based multinational conglomerate enter the gene therapy manufacturing space.
“Clearly, Ajinomoto is seeing this as a bet on the future of gene therapy, and that this will become a more important part of CDMO offerings into the future,” Forge board chair Chris Garabedian told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.